According to an FTC report, PBMs are central to the complex pharmaceutical distribution chain that delivers medicines from manufacturers to patients. PBMs serve as middlemen, negotiating the terms and conditions for prescription access. Those who work in the industry know this, but the critical question is, “What’s going to be done about it?”

In recent years, the medical community has increasingly recognized the link between obesity and cancer. Obesity is associated with an increased risk of several types of cancer, including breast, colon, endometrial, and pancreatic cancer, among others. Despite this clear connection, pharmaceutical companies have been notably silent on this issue in their patient education efforts.

Pharmacy benefit managers (PBMs) and pharmaceutical companies have been locked in a battle over the cost of prescription drugs for years. PBMs, third-party companies that administer prescription drug benefits for health insurers, argue that they are working to reduce drug costs for patients. Pharmaceutical companies, conversely, say that PBMs are using their market power to extract excessive rebates from drugmakers, which are passed on to patients through higher prices.